drugset
drugset / Trial / NCT01673386

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

NCT01673386 ↗

Phase 2 Terminated 58 enrolled AVEO Pharmaceuticals, Inc. Astellas Pharma Inc · collab
RandomizedCrossoverTriple-blindTreatment

Summary

Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).

Timeline

Start
2012-07
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sunitinib Small molecule 50 mg Oral
Subject Tivozanib Small molecule 1.5 mg Oral

Indications

renal cell carcinoma